Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9191915 | 0.85 | NPC1 (0.58) | NPC1RAB9AEPHX1EPHX2GAA | |
| SCHEMBL4093656 | 0.85 | EPHX1 (0.50) | NPC1RAB9AEPHX1EPHX2GAA | |
| SCHEMBL158280 | 0.83 | NPC1 (0.60) | NPC1RAB9AEPHX1EPHX2CA2 | |
| SCHEMBL31567937 | 0.83 | NPC1 (0.60) | NPC1RAB9AEPHX1EPHX2CA2 | |
| SCHEMBL3461319 | 0.82 | MEN1 (0.62) | NPC1RAB9AEPHX1EPHX2GAA | |
| SCHEMBL1092135 | 0.82 | EPHX1 (0.73) | NPC1RAB9AEPHX1EPHX2GAA | |
| SCHEMBL4831562 | 0.81 | NPC1 (0.73) | NPC1RAB9AKDM4EMAPTMEN1 | |
| Fluoride SCHEMBL11787935 | 0.80 | EPHX1 (0.70) | NPC1RAB9AEPHX1EPHX2GAA | |
| Hydrochloric Acid SCHEMBL11153269 | 0.80 | EPHX1 (0.70) | NPC1RAB9AEPHX1EPHX2GAA | |
| SCHEMBL5827751 | 0.80 | NPC1 (0.66) | NPC1RAB9AEPHX1EPHX2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| EP-3412670-A1 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-12 | — | — | EP | disclosed |
| US-10106507-B2 | Potent dual BRD4-kinase inhibitors as cancer therapeutics | H. Lee Moffitt Cancer Center and Research Insitute, Inc. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180290984-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2016022460-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
| US-20080214455-A1 | Novel Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1045829-B1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER CROPSCIENCE AG (DE) | 2003-06-04 | — | — | EP | disclosed |
| EP-1045829-A1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER AG (DE) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035122-A1 | METHOD FOR PRODUCING N-(3-AMINO-4-FLUOROPHENYL)- SULPHONAMIDES, N-(3-AMINO-4-FLUOROPHENYL) CARBOXYLIC ACID AMIDES AND N-(3-AMINO-4-FLUOROPHENYL) CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-15 | — | — | WO | disclosed |
| EP-0000815-B1 | PROCESS FOR PREPARING N-ARYL OR N-ARALKYL SUBSTITUTED URETHANES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4227008-A | CATALYTIC REACTION OF A NITRO-, NITROSO-, OR CARBAMATE-CONTAINING AROMATIC PRIMARY AMINE, AN ALCOHOL, AND CARBON MONOXIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1980-10-07 | — | — | US | disclosed |
| EP-0000815-A1 | Process for preparing N-aryl or N-aralkyl substituted urethanes | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1979-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | NPC1 3050/4885RAB9A 2858/4885EPHX1 3911/4885 |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | NPC1 3050/4885RAB9A 2858/4885EPHX1 3911/4885 |
| US-20180290984-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | NPC1 3050/4885RAB9A 2858/4885EPHX1 3911/4885 |
| US-10106507-B2 | Potent dual BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | NPC1 2578/4885RAB9A 2140/4885EPHX1 4158/4885 |
| US-20090270418-A1 | PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH | MAP3K1, MAP3K15, MAP3K5 | NPC1 2810/4885RAB9A 2850/4885EPHX1 2282/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | NPC1 2578/4885RAB9A 2140/4885EPHX1 4158/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | NPC1 3050/4885RAB9A 2858/4885EPHX1 3911/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | NPC1 2578/4885RAB9A 2140/4885EPHX1 4158/4885 |
| US-20080214455-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | NPC1 2040/4885RAB9A 1181/4885EPHX1 2224/4885 |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | BRAF, KDR, RAF1 | NPC1 4847/4885RAB9A 933/4885EPHX1 2031/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | NPC1 2040/4885RAB9A 1181/4885EPHX1 2224/4885 |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | BRAF, KDR, RAF1 | NPC1 4847/4885RAB9A 933/4885EPHX1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.